Development of Effective Drugs to Benefit the Global Clinical Trials Market

Market Overview:
The global market for Clinical Trials is anticipated to expand at an impressive CAGR of 5.7% during the forecast period from 2017 to 2023. This growth is attributable to the increasing investment in the healthcare industry, especially on the research and development of newer drugs and treatment in order to cater to the rising need for newer technologies globally. The clinical trials are the research study, which conducts the safety and efficacy test of the new drug. These trails are conducted for testing the wide-ranging drugs and medical devices.
The market growth is primarily relied on the key factors, including the increasing prevalence of chronic and long-term diseases coupled with increasing investment in the R&D sector globally. In addition to this, industrialization has led to increased disposable income, globalization, and increased awareness about the health and availability of several key and important drugs. These factors are driving growth of the global clinical trials market. However, lack of a skilled and trained workforce is restraining growth of the global clinical trials market. Also, high cost, stringent regulations, and unfavorable government policies are hampering growth of the global clinical trials market.
Nonetheless, factors such as the introduction of newer treatments, including innovation in technologies, personalized medicine, and rising demand for contract research organization (CROs) to conduct clinical trials, are likely to offer several opportunities for growth in the coming years. Further, the companies are increasingly adopting and accepting CROs for expansion of portfolio and drive innovations.
Access Full Report Details Exclusively @ https://www.marketresearchfuture.com/reports/clinical-trials-market-7787
Competitive Analysis:
·         Charles River Laboratories
·         Quintiles IMS
·         Paraxel International Corporation
·         ICON plc
·         Eli Lilly and Company
·         SGS SA
·         Novo Nordisk A/S
·         Laboratory Corporation of America
·         Clinipace
·         Pfizer
Segmentation:
·         The clinical trials market is segmented on phase, study design, indication, and end users.
·         By phase, the market is segmented into phase I, phase II, phase III, and phase IV.
·         By study design, the market is segmented into observational, interventional, and expanded access.
·         On the basis of indication, the market is segmented into pain management, autoimmune/inflammation, oncology, diabetes, central nervous system (CNS) condition, cardiovascular, obesity, and others.
·         Based on the end-user, the market is segmented into dental institutes and dental academic, dental hospitals & clinics, and research institutes.
Regional Analysis:
Regionally, the clinical trials market is segmented into the Americas, Asia Pacific, Europe, and Middle East & Africa. Of these, the Americas region is estimated to remain dominant in the global clinical trials market owing to the strong presence of several key players in the region. Furthermore, the strong presence of biotech companies, along with R&D units in the region are benefiting the market. Rising healthcare spending coupled with the presence of developed countries including the U.S. and Canada is fueling growth of the market.
Additionally, Europe is estimated to be on second-leading revenue share in the overall clinical trial market due to a surge in government support in terms of several policies; rising clinical trials across the private and government sector are enhancing the scope of the clinical trials market in the region. However, Asia Pacific is estimated to expand at the fastest CAGR during the forecast period owing to the presence of developing economies coupled with improving infrastructure in the region is also fueling growth of the global clinical trials market.
Industry News:
In 2019, Canada changed its regulations about making the clinical trial data and information public. This is estimated to increase transparency in their systems. Additionally, it will help to boost the awareness and knowledge about the clinical trials and the FDA’s working process.

Comments

Post a Comment

Popular posts from this blog

Proteomics Market Analysis, Demand Overview, Growth Analysis, Current Trends, Updates, and Global Industry Forecast to 2023

Market Highlights: The global proteomics market is anticipated to hold a market value of USD 23.2 billion in the year 2017 and is expected to grow at a CAGR of 14.1% during the forecast period. Proteomics is a science which is used to estimate the rate of protein production, interaction of proteins with one another, involvement of proteins in metabolic pathways, and modification of proteins. Also, it has extensive applications in drug discovery, development of personalized medicines, and identification of markers for disease diagnosis. Increasing need for personalized medicine, R&D expenditure, technological advancements and increased funding for proteomics project are expected to drive the market growth over the forecast period. For instance, in July 2017, Biognosys AG received USD 5 million funding from its new as well as existing investors. These new funds will be used for extending commercial operations and also to accelerate the development of next generation prote...
Read more

Pancreatic Cancer Market: America to Command the Largest Share

Market Overview: Pancreatic cancer can be defined as an enlarged tumor, which is generally caused by malignant cells present in the tissues of the pancreas. This type of cancer is generally caused due to drinking alcohol, smoking, genetic factors, radiotherapy in the past, obesity, inflammation of the pancreas, and diabetes mellitus. It is a type of cancer that starts in the pancreas and is a highly lethal disease. The global Pancreatic Cancer Market , as per a report by Market Research Future (MRFR) is touted to register 8.1% CAGR during the forecast period ( 2017-2023 ). The dearth of therapeutic approaches for early-stage detection has resulted in increased incidences of pancreatic cancer. Soaring prevalence of pancreatic cancer has resulted in germline mutations, thereby causing the defective genes to pass down to the children from their parents, thus making early detection of pancreatic cancer important. This has led to the growth of the market across the globe. Surging dem...
Read more

Immune Thrombocytopenia (ITP) Market is Estimated to Record Promising CAGR of 5.78% During Forecast 2018-2023

Market Highlights: As per the latest report published by Market Research Future (MRFR), the Global Immune Thrombocytopenia (ITP) is set to surpass a valuation of USD 2,300 Mn by the year 2023, reflecting a healthy CAGR. ITP is a blood related disorder that cause abnormal clotting. Some of the discomforts caused by the disease include bruising, bleeding and severe drop in platelets counts. Both minors and adults can develop the condition. The disease is classified into primary and secondary form. Primary form of ITP occurs on its own while the latter is an offshoot of another condition. The condition can be triggered by reactive medications, autoimmune disease, pregnancy and certain type of cancers. ITP is among the most commonly occurring disorder across the globe. In addition, the incidence rate has continued to spiral upwards in recent years. Factors as such as are fueling the demand for drugs and therapeutics for ITP. Currently, there are four treatment options available for ...
Read more